Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Zeffix 100 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Butterscotch coloured, film-coated, capsule shaped, biconvex, approximate dimensions 11mm x 5mm and engraved “GX CG5” on one face. |
Each film-coated tablet contains 100 mg lamivudine.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lamivudine |
Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription. |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose Tablet film coat: Hypromellose |
Double foil blisters, laminated with polyvinyl chloride.
Pack sizes of 28 or 84 film-coated tablets.
Not all pack-sizes may be marketed.
GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
EU/1/99/114/001
EU/1/99/114/002
Date of first authorisation: 29 July 1999
Date of latest renewal: 23 June 2014
| Drug | Countries | |
|---|---|---|
| ZEFFIX | Austria, Australia, Cyprus, Germany, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
